Repligen Stock News

Repligen (RGEN) launched three advanced affinity chromatography resins for use in gene therapy manufacturing workflows.The company said the resins — AVIPure - AAV9, AVIPure - AAV8,…

AVIPure® affinity resins address the market need for high performance and caustic stability AVIPure® affinity resins address the market need for high performance and caustic stability

Sector ETF report for PBE

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate

Repligen Corporation (NASDAQ:RGEN)s traded shares stood at 0.33 million during the last session, with the companys beta value hitting 0.91. At the close of trading, the stocks price was $188.97, to imply a decrease of -2.49% or -$4.82 in intraday trading. The RGEN shares 52-week high remains $327.32, putting it -73.21% down since that peak After The Stock Fell -5.96% Over The Week, Is Repligen Corporation (NASDAQ: RGEN) Still A Buy? Read More »

WALTHAM, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present vir

WALTHAM, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN ), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 11th Annual SVB Leerink Healthcare Conference being held Feb. 14-18, 2022. Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Friday, Feb. 18, at 3:00 p.m. EST. A live webcast of the presentation will be accessible through Repligen''s Full story available on Benzinga.com

WALTHAM, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtu

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

WASHINGTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Pharmaceutical Membrane Filtration Market finds that growth in the production of biopharmaceuticals is expediting market growth. Primarily driven by advancements in nanofiltration technologies, the total global Pharmaceutical Membrane Filtration Market is estimated to reach USD 14.16 Billion by 2028, up from USD 6.48 Billion in 2021, at a Compound Annual Growth Rate (CAGR) of 11.8%. Furthermore, the surging adoption of single-use technologies is also anticipated to augment the growth of the global Pharmaceutical Membrane Filtration Market, states Vantage Market Research, in a report, titled: " Pharmaceutical Membrane Filtration Market by Product (Filters, Systems, Accessories), by Technique (Microfiltration, Ultrafiltration, Nanofiltration, Reverse Osmosis), by Material (PES, PVDF, Nylon, PTFE), by Application (Final Product Processing, API Filtration, Sterile Filtration, Protein Purification), by Region (North America, Europe, Asia Pacific, Middle East & Africa) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

Stocks, especially the once high flying technology stocks, had a lousy start to the new year. QQQ lost 9% of its value in January.

Webcast and Conference Call to Be Held Thursday, February 17, 2022 at 8:30 a.m. EST Webcast and Conference Call to Be Held Thursday, February 17, 2022 at 8:30 a.m. EST

Webcast and Conference Call to Be Held Thursday, February 17, 2022 at 8:30 a.m. EST Webcast and Conference Call to Be Held Thursday, February 17, 2022 at 8:30 a.m. EST

Webcast and Conference Call to Be Held Thursday, February 17, 2022 at 8:30 a.m. EST Webcast and Conference Call to Be Held Thursday, February 17, 2022 at 8:30 a.m. EST